AstraZeneca Cuts Drug Prices, Invests $50B in U.S.
AstraZeneca and the Shift in U.S. Pharmaceutical Pricing A major development has taken place in the U.S. pharmaceutical sector, with British global pharmaceutical company AstraZeneca announcing an agreement to lower drug prices under the administration of former U.S. President Donald Trump. This move follows a similar deal made with Pfizer, marking a significant shift in how pharmaceutical companies are responding to pressure from the government. On the 10th of last month, Trump announced the agreement at the White House, stating that AstraZeneca would supply all prescription drugs to Medicaid, which serves low-income individuals, at the most-favored-nation (MFN) price. The MFN price refers to the lowest price that pharmaceutical companies offer to developed countries outside the U.S. In addition to this, AstraZeneca agreed to sell all medicines launched in the U.S. market at discounted prices and invest $50 billion in the U.S. over the next five years. As part of the deal, the comp...